| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cocaine-Related Disorders | 23 | 2013 | 504 | 3.180 |
Why?
|
| Alcoholism | 31 | 2023 | 1109 | 2.180 |
Why?
|
| Substance Withdrawal Syndrome | 24 | 2016 | 435 | 1.940 |
Why?
|
| Substance-Related Disorders | 26 | 2016 | 1242 | 1.510 |
Why?
|
| Ethanol | 15 | 2017 | 893 | 1.420 |
Why?
|
| Anticonvulsants | 13 | 2007 | 223 | 1.330 |
Why?
|
| Acetylcysteine | 8 | 2020 | 296 | 1.270 |
Why?
|
| gamma-Aminobutyric Acid | 9 | 2016 | 208 | 1.210 |
Why?
|
| Cyclohexanecarboxylic Acids | 8 | 2016 | 60 | 1.130 |
Why?
|
| Amines | 8 | 2016 | 98 | 1.100 |
Why?
|
| Methylphenidate | 5 | 2017 | 97 | 1.090 |
Why?
|
| Weight Reduction Programs | 8 | 2021 | 67 | 1.090 |
Why?
|
| Dexmethylphenidate Hydrochloride | 3 | 2017 | 12 | 1.080 |
Why?
|
| Amlodipine | 4 | 2009 | 31 | 0.960 |
Why?
|
| Affect | 6 | 2015 | 218 | 0.940 |
Why?
|
| Adult | 93 | 2021 | 21403 | 0.830 |
Why?
|
| Double-Blind Method | 28 | 2023 | 1738 | 0.820 |
Why?
|
| Central Nervous System Stimulants | 9 | 2017 | 221 | 0.820 |
Why?
|
| Weight Loss | 11 | 2021 | 319 | 0.790 |
Why?
|
| Disulfiram | 3 | 2010 | 22 | 0.770 |
Why?
|
| Psychiatric Status Rating Scales | 14 | 2013 | 782 | 0.730 |
Why?
|
| Obesity | 18 | 2021 | 1076 | 0.730 |
Why?
|
| Humans | 141 | 2023 | 68618 | 0.720 |
Why?
|
| Benzodiazepines | 8 | 2016 | 130 | 0.720 |
Why?
|
| Calcium Channel Blockers | 3 | 2009 | 138 | 0.720 |
Why?
|
| Male | 101 | 2021 | 37321 | 0.710 |
Why?
|
| Lorazepam | 5 | 2009 | 54 | 0.650 |
Why?
|
| Female | 95 | 2020 | 38074 | 0.650 |
Why?
|
| Middle Aged | 64 | 2020 | 21147 | 0.630 |
Why?
|
| GABA Modulators | 2 | 2009 | 26 | 0.630 |
Why?
|
| Clinical Trials as Topic | 9 | 2014 | 848 | 0.590 |
Why?
|
| Obsessive-Compulsive Disorder | 2 | 2011 | 88 | 0.550 |
Why?
|
| Amino Acid Transport System y+ | 2 | 2013 | 13 | 0.530 |
Why?
|
| Benzhydryl Compounds | 5 | 2010 | 62 | 0.510 |
Why?
|
| Pergolide | 4 | 2001 | 12 | 0.500 |
Why?
|
| Alcohol Withdrawal Delirium | 5 | 2006 | 24 | 0.500 |
Why?
|
| Alcohol Deterrents | 4 | 2010 | 86 | 0.500 |
Why?
|
| Anti-Anxiety Agents | 5 | 2002 | 107 | 0.480 |
Why?
|
| Surveys and Questionnaires | 6 | 2014 | 2800 | 0.480 |
Why?
|
| Schizophrenia | 4 | 2012 | 206 | 0.470 |
Why?
|
| Cognition | 3 | 2021 | 513 | 0.460 |
Why?
|
| Nicotine | 4 | 2013 | 350 | 0.460 |
Why?
|
| Carbamazepine | 6 | 2002 | 108 | 0.460 |
Why?
|
| Behavior, Addictive | 4 | 2007 | 317 | 0.440 |
Why?
|
| Treatment Outcome | 24 | 2023 | 7029 | 0.440 |
Why?
|
| Mental Disorders | 6 | 2015 | 659 | 0.440 |
Why?
|
| Valproic Acid | 5 | 2001 | 93 | 0.440 |
Why?
|
| Reflex, Startle | 1 | 2013 | 39 | 0.430 |
Why?
|
| Family Health | 1 | 2013 | 83 | 0.420 |
Why?
|
| Nicotinic Agonists | 1 | 2013 | 111 | 0.410 |
Why?
|
| Cocaine | 12 | 2006 | 555 | 0.410 |
Why?
|
| Acetates | 5 | 2004 | 74 | 0.390 |
Why?
|
| Naltrexone | 8 | 2001 | 195 | 0.380 |
Why?
|
| Education, Medical, Continuing | 1 | 2012 | 136 | 0.380 |
Why?
|
| Adolescent | 22 | 2020 | 8912 | 0.380 |
Why?
|
| Psychiatry | 1 | 2012 | 112 | 0.380 |
Why?
|
| Marijuana Abuse | 5 | 2017 | 251 | 0.380 |
Why?
|
| Young Adult | 16 | 2021 | 5717 | 0.370 |
Why?
|
| Alcohol-Induced Disorders, Nervous System | 1 | 2010 | 11 | 0.360 |
Why?
|
| Medicaid | 1 | 2012 | 302 | 0.350 |
Why?
|
| Hunger | 3 | 2020 | 27 | 0.340 |
Why?
|
| Smoking | 4 | 2013 | 1452 | 0.340 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 438 | 0.340 |
Why?
|
| Flumazenil | 1 | 2009 | 23 | 0.340 |
Why?
|
| Alcohol-Induced Disorders | 2 | 2006 | 5 | 0.330 |
Why?
|
| Nipecotic Acids | 2 | 2005 | 11 | 0.330 |
Why?
|
| Drug Interactions | 10 | 2017 | 289 | 0.330 |
Why?
|
| Fructose | 3 | 2013 | 51 | 0.330 |
Why?
|
| Behavior Therapy | 9 | 2013 | 297 | 0.320 |
Why?
|
| Models, Statistical | 3 | 2008 | 448 | 0.320 |
Why?
|
| Psychometrics | 1 | 2011 | 514 | 0.320 |
Why?
|
| Ambulatory Care | 6 | 2005 | 340 | 0.310 |
Why?
|
| Cross-Over Studies | 7 | 2017 | 260 | 0.310 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2008 | 931 | 0.300 |
Why?
|
| Glutamic Acid | 1 | 2011 | 332 | 0.300 |
Why?
|
| Stress Disorders, Post-Traumatic | 5 | 2023 | 1506 | 0.300 |
Why?
|
| Hospitalization | 10 | 2011 | 978 | 0.300 |
Why?
|
| Crack Cocaine | 3 | 2006 | 20 | 0.290 |
Why?
|
| Alcohol Drinking | 8 | 2009 | 805 | 0.290 |
Why?
|
| Random Allocation | 5 | 2006 | 442 | 0.290 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 329 | 0.280 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2007 | 28 | 0.280 |
Why?
|
| Free Radical Scavengers | 1 | 2006 | 112 | 0.270 |
Why?
|
| Follow-Up Studies | 12 | 2016 | 3259 | 0.270 |
Why?
|
| Cannabidiol | 2 | 2016 | 31 | 0.270 |
Why?
|
| GABA Agonists | 1 | 2005 | 23 | 0.260 |
Why?
|
| Blood Pressure | 6 | 2016 | 1451 | 0.260 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2009 | 1745 | 0.260 |
Why?
|
| Drug Therapy | 2 | 2006 | 71 | 0.250 |
Why?
|
| Marijuana Smoking | 2 | 2016 | 108 | 0.250 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2020 | 1085 | 0.240 |
Why?
|
| Veterans | 4 | 2023 | 904 | 0.240 |
Why?
|
| Relaxation Therapy | 2 | 2003 | 19 | 0.240 |
Why?
|
| Pilot Projects | 9 | 2021 | 1342 | 0.240 |
Why?
|
| Administration, Oral | 8 | 2017 | 411 | 0.230 |
Why?
|
| Quality of Life | 4 | 2021 | 1515 | 0.230 |
Why?
|
| Feeding and Eating Disorders | 2 | 2003 | 106 | 0.230 |
Why?
|
| Overweight | 4 | 2020 | 186 | 0.230 |
Why?
|
| Hypnotics and Sedatives | 5 | 2009 | 96 | 0.230 |
Why?
|
| Time Factors | 8 | 2009 | 4655 | 0.230 |
Why?
|
| Headache | 2 | 2002 | 68 | 0.220 |
Why?
|
| Comorbidity | 10 | 2016 | 1426 | 0.220 |
Why?
|
| Receptors, GABA | 1 | 2003 | 8 | 0.220 |
Why?
|
| Diet, Reducing | 5 | 2013 | 46 | 0.220 |
Why?
|
| Neuroprotective Agents | 1 | 2006 | 317 | 0.220 |
Why?
|
| Secondary Prevention | 3 | 2013 | 291 | 0.210 |
Why?
|
| Dopamine Agonists | 2 | 2000 | 68 | 0.210 |
Why?
|
| Combined Modality Therapy | 7 | 2020 | 951 | 0.200 |
Why?
|
| Amphetamine-Related Disorders | 2 | 2013 | 92 | 0.190 |
Why?
|
| GABA Agents | 1 | 2001 | 18 | 0.190 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2021 | 41 | 0.190 |
Why?
|
| Transcranial Magnetic Stimulation | 2 | 2017 | 413 | 0.190 |
Why?
|
| Resilience, Psychological | 1 | 2021 | 43 | 0.190 |
Why?
|
| Buspirone | 3 | 2001 | 36 | 0.180 |
Why?
|
| Sleep Wake Disorders | 1 | 2002 | 94 | 0.180 |
Why?
|
| Liver Transplantation | 2 | 2015 | 400 | 0.180 |
Why?
|
| Tobacco Use Disorder | 4 | 2008 | 432 | 0.180 |
Why?
|
| Opioid-Related Disorders | 4 | 2014 | 298 | 0.180 |
Why?
|
| Methamphetamine | 2 | 2013 | 132 | 0.180 |
Why?
|
| Anxiety Disorders | 3 | 2006 | 426 | 0.180 |
Why?
|
| Depressive Disorder | 4 | 1991 | 621 | 0.180 |
Why?
|
| Cardiovascular Diseases | 4 | 2016 | 940 | 0.170 |
Why?
|
| Electromyography | 2 | 2013 | 184 | 0.170 |
Why?
|
| Aged | 16 | 2020 | 14862 | 0.160 |
Why?
|
| Craving | 2 | 2017 | 200 | 0.160 |
Why?
|
| Infusions, Intravenous | 3 | 2009 | 334 | 0.160 |
Why?
|
| Severity of Illness Index | 4 | 2007 | 1851 | 0.160 |
Why?
|
| Dietary Supplements | 1 | 2021 | 332 | 0.160 |
Why?
|
| Military Personnel | 1 | 2021 | 221 | 0.160 |
Why?
|
| Heart Rate | 3 | 2016 | 568 | 0.160 |
Why?
|
| Cause of Death | 2 | 2015 | 241 | 0.160 |
Why?
|
| Transferrin | 1 | 1999 | 94 | 0.160 |
Why?
|
| Stereoisomerism | 4 | 2012 | 169 | 0.150 |
Why?
|
| Cognitive Dysfunction | 1 | 2021 | 176 | 0.150 |
Why?
|
| Patient Dropouts | 3 | 2008 | 98 | 0.150 |
Why?
|
| Risk Factors | 9 | 2016 | 5731 | 0.150 |
Why?
|
| Recurrence | 5 | 2009 | 948 | 0.150 |
Why?
|
| Analgesics, Opioid | 3 | 2014 | 498 | 0.140 |
Why?
|
| Psychosocial Support Systems | 1 | 2017 | 12 | 0.140 |
Why?
|
| Electrocardiography | 1 | 1999 | 601 | 0.140 |
Why?
|
| Temperance | 2 | 2009 | 41 | 0.140 |
Why?
|
| Drug Synergism | 2 | 2015 | 260 | 0.140 |
Why?
|
| Anxiety | 5 | 2009 | 422 | 0.140 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 3 | 2008 | 91 | 0.140 |
Why?
|
| Cues | 2 | 2013 | 654 | 0.140 |
Why?
|
| Substance Abuse Treatment Centers | 3 | 2010 | 71 | 0.130 |
Why?
|
| Area Under Curve | 3 | 2012 | 238 | 0.130 |
Why?
|
| Obesity, Morbid | 2 | 2017 | 172 | 0.130 |
Why?
|
| Patient Compliance | 4 | 2005 | 402 | 0.130 |
Why?
|
| Eating | 2 | 2014 | 119 | 0.130 |
Why?
|
| Combat Disorders | 1 | 2016 | 102 | 0.130 |
Why?
|
| United States | 7 | 2021 | 7367 | 0.130 |
Why?
|
| Life Style | 2 | 2017 | 338 | 0.130 |
Why?
|
| Sensitivity and Specificity | 3 | 2016 | 1753 | 0.130 |
Why?
|
| Carbon Monoxide | 2 | 2013 | 58 | 0.130 |
Why?
|
| Dronabinol | 1 | 2015 | 84 | 0.120 |
Why?
|
| Body Weight | 8 | 2020 | 554 | 0.120 |
Why?
|
| Analysis of Variance | 4 | 2012 | 1040 | 0.120 |
Why?
|
| Smoking Prevention | 2 | 2007 | 259 | 0.120 |
Why?
|
| Marital Status | 1 | 2014 | 65 | 0.120 |
Why?
|
| Emotions | 2 | 2014 | 244 | 0.120 |
Why?
|
| Central Nervous System Depressants | 3 | 2007 | 182 | 0.120 |
Why?
|
| Body Mass Index | 4 | 2021 | 867 | 0.110 |
Why?
|
| Drug Therapy, Combination | 3 | 2013 | 649 | 0.110 |
Why?
|
| Social Control, Informal | 1 | 2013 | 8 | 0.110 |
Why?
|
| Placebos | 4 | 2007 | 195 | 0.110 |
Why?
|
| Prefrontal Cortex | 3 | 2017 | 640 | 0.110 |
Why?
|
| Mood Disorders | 2 | 2002 | 132 | 0.110 |
Why?
|
| Antipsychotic Agents | 2 | 2006 | 247 | 0.110 |
Why?
|
| Conditioning, Eyelid | 1 | 2013 | 2 | 0.110 |
Why?
|
| Neuropsychological Tests | 2 | 2021 | 517 | 0.110 |
Why?
|
| Bariatric Surgery | 1 | 2014 | 90 | 0.110 |
Why?
|
| Psychological Tests | 1 | 2013 | 96 | 0.110 |
Why?
|
| Carboxylesterase | 1 | 2012 | 4 | 0.110 |
Why?
|
| Esterification | 1 | 2012 | 25 | 0.110 |
Why?
|
| Substance Abuse Detection | 2 | 2005 | 66 | 0.110 |
Why?
|
| Injections, Intravenous | 1 | 2013 | 215 | 0.110 |
Why?
|
| Motivation | 3 | 2005 | 561 | 0.110 |
Why?
|
| Anti-Obesity Agents | 1 | 2013 | 42 | 0.110 |
Why?
|
| Heart Failure | 1 | 2021 | 1180 | 0.110 |
Why?
|
| Acoustic Stimulation | 1 | 2013 | 206 | 0.100 |
Why?
|
| Violence | 1 | 2014 | 275 | 0.100 |
Why?
|
| Pancreatitis, Chronic | 1 | 2014 | 168 | 0.100 |
Why?
|
| End Stage Liver Disease | 1 | 2012 | 60 | 0.100 |
Why?
|
| Chi-Square Distribution | 3 | 2002 | 546 | 0.100 |
Why?
|
| Thioridazine | 2 | 1989 | 6 | 0.100 |
Why?
|
| Obsessive Behavior | 1 | 2011 | 6 | 0.100 |
Why?
|
| Compulsive Behavior | 1 | 2011 | 12 | 0.100 |
Why?
|
| Nurse Practitioners | 1 | 2012 | 90 | 0.100 |
Why?
|
| Narcotic Antagonists | 3 | 2007 | 184 | 0.100 |
Why?
|
| Outpatients | 2 | 2002 | 127 | 0.100 |
Why?
|
| Analgesics | 1 | 2012 | 118 | 0.100 |
Why?
|
| Smoking Cessation | 4 | 2007 | 1034 | 0.100 |
Why?
|
| Family | 2 | 2013 | 293 | 0.100 |
Why?
|
| Phobic Disorders | 2 | 1991 | 227 | 0.100 |
Why?
|
| Socioeconomic Factors | 4 | 2020 | 955 | 0.090 |
Why?
|
| Chronic Pain | 1 | 2012 | 110 | 0.090 |
Why?
|
| Logistic Models | 3 | 2009 | 1420 | 0.090 |
Why?
|
| Public Sector | 1 | 2010 | 19 | 0.090 |
Why?
|
| Blood Glucose | 4 | 2016 | 631 | 0.090 |
Why?
|
| Pain Management | 1 | 2012 | 186 | 0.090 |
Why?
|
| Reproducibility of Results | 3 | 2013 | 2077 | 0.090 |
Why?
|
| Pain | 1 | 2014 | 472 | 0.090 |
Why?
|
| Brain | 4 | 2010 | 2176 | 0.090 |
Why?
|
| Dopamine beta-Hydroxylase | 1 | 2010 | 24 | 0.090 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 2 | 2007 | 19 | 0.090 |
Why?
|
| Treatment Failure | 2 | 2001 | 216 | 0.090 |
Why?
|
| Animals | 11 | 2014 | 20881 | 0.090 |
Why?
|
| Cholesterol | 3 | 2016 | 331 | 0.090 |
Why?
|
| Schizophrenic Psychology | 2 | 1991 | 53 | 0.090 |
Why?
|
| Retrospective Studies | 6 | 2016 | 7277 | 0.090 |
Why?
|
| Hemodynamics | 1 | 2012 | 705 | 0.090 |
Why?
|
| Oxazepam | 1 | 1989 | 3 | 0.080 |
Why?
|
| Brain Chemistry | 1 | 2010 | 173 | 0.080 |
Why?
|
| South Carolina | 4 | 2012 | 2752 | 0.080 |
Why?
|
| Patient Selection | 3 | 2009 | 592 | 0.080 |
Why?
|
| Bulimia | 1 | 1989 | 72 | 0.080 |
Why?
|
| Septum Pellucidum | 1 | 1989 | 7 | 0.080 |
Why?
|
| Lung Diseases, Obstructive | 1 | 1989 | 20 | 0.080 |
Why?
|
| Stress, Psychological | 2 | 2003 | 824 | 0.080 |
Why?
|
| Asphyxia | 1 | 1989 | 8 | 0.080 |
Why?
|
| Psychoses, Substance-Induced | 5 | 1997 | 20 | 0.080 |
Why?
|
| Sick Role | 1 | 1989 | 40 | 0.080 |
Why?
|
| Neurocognitive Disorders | 1 | 1989 | 23 | 0.080 |
Why?
|
| Excitatory Amino Acid Transporter 2 | 1 | 2008 | 26 | 0.080 |
Why?
|
| Dietary Carbohydrates | 1 | 2008 | 27 | 0.080 |
Why?
|
| Triglycerides | 3 | 2016 | 184 | 0.080 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2009 | 128 | 0.080 |
Why?
|
| Telemedicine | 1 | 2017 | 700 | 0.080 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2008 | 26 | 0.080 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2008 | 26 | 0.080 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2008 | 58 | 0.080 |
Why?
|
| Drug Administration Schedule | 5 | 2007 | 567 | 0.080 |
Why?
|
| Prisoners | 2 | 2009 | 50 | 0.080 |
Why?
|
| Executive Function | 1 | 2009 | 106 | 0.080 |
Why?
|
| Referral and Consultation | 2 | 1989 | 383 | 0.080 |
Why?
|
| Psychotherapy | 2 | 2016 | 253 | 0.080 |
Why?
|
| Monte Carlo Method | 1 | 2008 | 124 | 0.080 |
Why?
|
| Bias | 1 | 2008 | 148 | 0.080 |
Why?
|
| Sleep Deprivation | 1 | 1988 | 81 | 0.070 |
Why?
|
| Medical Staff, Hospital | 1 | 1987 | 44 | 0.070 |
Why?
|
| Sleep | 1 | 2009 | 263 | 0.070 |
Why?
|
| Attention | 1 | 2009 | 225 | 0.070 |
Why?
|
| Prospective Studies | 4 | 2020 | 3705 | 0.070 |
Why?
|
| Length of Stay | 2 | 2011 | 780 | 0.070 |
Why?
|
| Ganglionic Stimulants | 1 | 2007 | 15 | 0.070 |
Why?
|
| Electronic Mail | 2 | 2017 | 29 | 0.070 |
Why?
|
| Nursing Staff, Hospital | 1 | 1987 | 62 | 0.070 |
Why?
|
| Cotinine | 1 | 2007 | 40 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2010 | 659 | 0.070 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1987 | 123 | 0.070 |
Why?
|
| Chewing Gum | 1 | 1986 | 6 | 0.070 |
Why?
|
| Research Design | 2 | 2008 | 729 | 0.070 |
Why?
|
| Metabolic Syndrome | 1 | 2008 | 191 | 0.070 |
Why?
|
| Inactivation, Metabolic | 1 | 2006 | 28 | 0.070 |
Why?
|
| Buprenorphine | 1 | 2007 | 67 | 0.070 |
Why?
|
| Diazepam | 1 | 2006 | 23 | 0.070 |
Why?
|
| Blood Urea Nitrogen | 1 | 2006 | 65 | 0.070 |
Why?
|
| Surgical Procedures, Operative | 1 | 2007 | 124 | 0.070 |
Why?
|
| Visual Perception | 1 | 2007 | 124 | 0.070 |
Why?
|
| Facial Muscles | 1 | 1986 | 11 | 0.070 |
Why?
|
| Telephone | 2 | 2017 | 160 | 0.070 |
Why?
|
| Silver | 1 | 1986 | 49 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 2223 | 0.070 |
Why?
|
| Appetite | 2 | 2003 | 16 | 0.070 |
Why?
|
| Medication Adherence | 1 | 2009 | 335 | 0.070 |
Why?
|
| Biomarkers | 2 | 2004 | 1593 | 0.070 |
Why?
|
| Mutation | 2 | 2008 | 1213 | 0.060 |
Why?
|
| Cross-Sectional Studies | 5 | 2014 | 2279 | 0.060 |
Why?
|
| Creatinine | 1 | 2006 | 243 | 0.060 |
Why?
|
| Patient Admission | 1 | 2006 | 99 | 0.060 |
Why?
|
| Kindling, Neurologic | 2 | 2000 | 24 | 0.060 |
Why?
|
| Safety | 1 | 2006 | 145 | 0.060 |
Why?
|
| Synaptic Transmission | 2 | 2007 | 236 | 0.060 |
Why?
|
| Statistics as Topic | 1 | 2006 | 219 | 0.060 |
Why?
|
| Reinforcement Schedule | 1 | 2005 | 59 | 0.060 |
Why?
|
| Self Administration | 3 | 2015 | 419 | 0.060 |
Why?
|
| Computer Simulation | 1 | 2008 | 706 | 0.060 |
Why?
|
| Pain, Postoperative | 1 | 2007 | 214 | 0.060 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 2 | 2016 | 151 | 0.060 |
Why?
|
| Demography | 1 | 2005 | 279 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2008 | 1054 | 0.060 |
Why?
|
| Societies, Medical | 2 | 2004 | 403 | 0.060 |
Why?
|
| Neurologic Examination | 2 | 2006 | 107 | 0.060 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2004 | 17 | 0.060 |
Why?
|
| Alcohol-Related Disorders | 2 | 2003 | 95 | 0.060 |
Why?
|
| Feeding Behavior | 2 | 2003 | 224 | 0.060 |
Why?
|
| Bupropion | 1 | 2004 | 63 | 0.060 |
Why?
|
| Psychotherapy, Group | 1 | 2004 | 55 | 0.060 |
Why?
|
| Narcolepsy | 1 | 2004 | 45 | 0.060 |
Why?
|
| Protein Interaction Mapping | 1 | 2003 | 62 | 0.060 |
Why?
|
| Drosophila Proteins | 1 | 2003 | 44 | 0.060 |
Why?
|
| Waist Circumference | 2 | 2016 | 32 | 0.060 |
Why?
|
| Reward | 1 | 2005 | 201 | 0.060 |
Why?
|
| Affective Symptoms | 1 | 2003 | 50 | 0.050 |
Why?
|
| Electroconvulsive Therapy | 1 | 1988 | 402 | 0.050 |
Why?
|
| Sexual Partners | 1 | 2004 | 106 | 0.050 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2023 | 20 | 0.050 |
Why?
|
| Doxazosin | 1 | 2023 | 20 | 0.050 |
Why?
|
| Family Therapy | 1 | 2004 | 82 | 0.050 |
Why?
|
| Proteome | 1 | 2003 | 87 | 0.050 |
Why?
|
| Metabolic Clearance Rate | 1 | 2002 | 48 | 0.050 |
Why?
|
| Drosophila melanogaster | 1 | 2003 | 80 | 0.050 |
Why?
|
| Cholesterol, HDL | 2 | 2016 | 112 | 0.050 |
Why?
|
| Syndrome | 1 | 2003 | 255 | 0.050 |
Why?
|
| Hallucinations | 3 | 1991 | 19 | 0.050 |
Why?
|
| Personality Inventory | 2 | 2001 | 197 | 0.050 |
Why?
|
| Poisson Distribution | 1 | 2002 | 85 | 0.050 |
Why?
|
| Sex Factors | 4 | 2020 | 1266 | 0.050 |
Why?
|
| Work Capacity Evaluation | 1 | 2002 | 8 | 0.050 |
Why?
|
| Models, Psychological | 1 | 2003 | 180 | 0.050 |
Why?
|
| Health Behavior | 2 | 2020 | 458 | 0.050 |
Why?
|
| Ritanserin | 1 | 2001 | 5 | 0.050 |
Why?
|
| Exercise Tolerance | 1 | 2021 | 75 | 0.050 |
Why?
|
| Adjuvants, Anesthesia | 1 | 2001 | 8 | 0.050 |
Why?
|
| Serotonin Agents | 1 | 2001 | 13 | 0.050 |
Why?
|
| Vigabatrin | 1 | 2001 | 8 | 0.050 |
Why?
|
| Phospholipids | 1 | 2021 | 108 | 0.050 |
Why?
|
| Energy Intake | 1 | 2021 | 123 | 0.050 |
Why?
|
| Social Support | 1 | 2004 | 423 | 0.050 |
Why?
|
| Sodium Oxybate | 1 | 2001 | 13 | 0.050 |
Why?
|
| Counseling | 2 | 2016 | 280 | 0.050 |
Why?
|
| Taurine | 1 | 2001 | 51 | 0.050 |
Why?
|
| Patient Education as Topic | 2 | 2017 | 425 | 0.040 |
Why?
|
| Parenteral Nutrition, Total | 1 | 1980 | 22 | 0.040 |
Why?
|
| Parenteral Nutrition | 1 | 1980 | 39 | 0.040 |
Why?
|
| Chickenpox | 1 | 1979 | 14 | 0.040 |
Why?
|
| Pancytopenia | 1 | 1979 | 10 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2000 | 306 | 0.040 |
Why?
|
| Taste | 1 | 1980 | 49 | 0.040 |
Why?
|
| Single-Blind Method | 2 | 2013 | 249 | 0.040 |
Why?
|
| Health Surveys | 2 | 2012 | 489 | 0.040 |
Why?
|
| Functional Laterality | 2 | 2013 | 240 | 0.040 |
Why?
|
| Forensic Medicine | 1 | 1999 | 26 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2021 | 586 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1989 | 2324 | 0.040 |
Why?
|
| Burns | 1 | 1980 | 83 | 0.040 |
Why?
|
| Sleep Stages | 2 | 2008 | 30 | 0.040 |
Why?
|
| Liver | 2 | 1999 | 1118 | 0.040 |
Why?
|
| Cerebrovascular Circulation | 1 | 1999 | 296 | 0.040 |
Why?
|
| Biological Availability | 1 | 2017 | 79 | 0.040 |
Why?
|
| Pharmacogenetics | 2 | 2008 | 47 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2017 | 78 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 378 | 0.040 |
Why?
|
| Administration, Sublingual | 2 | 2007 | 15 | 0.040 |
Why?
|
| Phencyclidine | 1 | 1976 | 17 | 0.040 |
Why?
|
| Administration, Intranasal | 3 | 2007 | 88 | 0.040 |
Why?
|
| Age Factors | 3 | 2020 | 1864 | 0.030 |
Why?
|
| Sex Distribution | 2 | 2012 | 274 | 0.030 |
Why?
|
| Methadone | 1 | 2016 | 32 | 0.030 |
Why?
|
| Borderline Personality Disorder | 1 | 1996 | 13 | 0.030 |
Why?
|
| Hospitals, Veterans | 2 | 1996 | 147 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 180 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2016 | 161 | 0.030 |
Why?
|
| Self-Injurious Behavior | 1 | 1996 | 31 | 0.030 |
Why?
|
| Opiate Substitution Treatment | 1 | 2016 | 57 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2017 | 158 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 2016 | 213 | 0.030 |
Why?
|
| Health Education | 1 | 2016 | 279 | 0.030 |
Why?
|
| Panic Disorder | 1 | 1994 | 121 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2006 | 381 | 0.030 |
Why?
|
| Fasting | 1 | 2013 | 75 | 0.030 |
Why?
|
| Heroin Dependence | 1 | 1993 | 23 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 137 | 0.030 |
Why?
|
| Phentermine | 1 | 2013 | 17 | 0.030 |
Why?
|
| Photic Stimulation | 1 | 2013 | 229 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2014 | 397 | 0.030 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2013 | 257 | 0.030 |
Why?
|
| Social Adjustment | 1 | 1992 | 74 | 0.030 |
Why?
|
| Benzazepines | 1 | 2013 | 104 | 0.030 |
Why?
|
| Movement | 1 | 2013 | 179 | 0.030 |
Why?
|
| Dimenhydrinate | 1 | 1972 | 1 | 0.030 |
Why?
|
| Erythrocyte Aggregation | 1 | 1972 | 2 | 0.030 |
Why?
|
| Microcirculation | 1 | 1972 | 77 | 0.020 |
Why?
|
| Aftercare | 1 | 1992 | 114 | 0.020 |
Why?
|
| Age Distribution | 1 | 2012 | 320 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2012 | 328 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2013 | 502 | 0.020 |
Why?
|
| Seizures | 1 | 2013 | 279 | 0.020 |
Why?
|
| Depression | 2 | 2009 | 943 | 0.020 |
Why?
|
| Agoraphobia | 1 | 1991 | 59 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2012 | 319 | 0.020 |
Why?
|
| Panic | 1 | 1991 | 97 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2012 | 737 | 0.020 |
Why?
|
| Psychotropic Drugs | 1 | 1991 | 83 | 0.020 |
Why?
|
| Health Services | 1 | 2011 | 87 | 0.020 |
Why?
|
| Nonprescription Drugs | 2 | 1988 | 28 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 1991 | 107 | 0.020 |
Why?
|
| Utilization Review | 1 | 1990 | 48 | 0.020 |
Why?
|
| Tranquilizing Agents | 1 | 2009 | 7 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2010 | 166 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2007 | 2791 | 0.020 |
Why?
|
| Thinking | 1 | 1989 | 30 | 0.020 |
Why?
|
| Internal-External Control | 1 | 1989 | 60 | 0.020 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2010 | 75 | 0.020 |
Why?
|
| Platybasia | 1 | 1989 | 2 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 1972 | 470 | 0.020 |
Why?
|
| Attitude | 1 | 1989 | 121 | 0.020 |
Why?
|
| Health Expenditures | 1 | 2011 | 170 | 0.020 |
Why?
|
| Remission Induction | 1 | 2008 | 111 | 0.020 |
Why?
|
| Income | 1 | 2009 | 167 | 0.020 |
Why?
|
| Frameshift Mutation | 1 | 2008 | 8 | 0.020 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 1988 | 21 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2008 | 15 | 0.020 |
Why?
|
| Child | 2 | 2010 | 6405 | 0.020 |
Why?
|
| Caffeine | 1 | 1988 | 81 | 0.020 |
Why?
|
| Insurance, Health | 1 | 1990 | 201 | 0.020 |
Why?
|
| Appetite Depressants | 1 | 1988 | 11 | 0.020 |
Why?
|
| Psychoses, Alcoholic | 1 | 1988 | 5 | 0.020 |
Why?
|
| Self Medication | 1 | 2008 | 25 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 1990 | 188 | 0.020 |
Why?
|
| Ventral Tegmental Area | 1 | 2008 | 74 | 0.020 |
Why?
|
| Stomach | 1 | 1988 | 80 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 1989 | 76 | 0.020 |
Why?
|
| Body Composition | 1 | 2008 | 119 | 0.020 |
Why?
|
| Point Mutation | 1 | 2008 | 97 | 0.020 |
Why?
|
| Acute Disease | 2 | 1980 | 658 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2008 | 137 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2008 | 207 | 0.020 |
Why?
|
| Depressive Disorder, Major | 1 | 2012 | 439 | 0.020 |
Why?
|
| Prevalence | 1 | 2012 | 1619 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2008 | 99 | 0.020 |
Why?
|
| DNA Primers | 1 | 2008 | 302 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2008 | 234 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2008 | 371 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 1984 | 1140 | 0.020 |
Why?
|
| Nurse-Patient Relations | 1 | 1987 | 34 | 0.020 |
Why?
|
| Social Perception | 1 | 1987 | 44 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2008 | 210 | 0.020 |
Why?
|
| Naloxone | 1 | 2007 | 56 | 0.020 |
Why?
|
| Amygdala | 1 | 2008 | 159 | 0.020 |
Why?
|
| Alleles | 1 | 2008 | 386 | 0.020 |
Why?
|
| Prostheses and Implants | 1 | 1988 | 159 | 0.020 |
Why?
|
| Biotransformation | 1 | 2007 | 69 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2007 | 87 | 0.020 |
Why?
|
| Respiratory Mechanics | 1 | 2007 | 33 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 2007 | 80 | 0.020 |
Why?
|
| Physician-Patient Relations | 2 | 1987 | 261 | 0.020 |
Why?
|
| Public Health | 1 | 2008 | 201 | 0.020 |
Why?
|
| Exercise Therapy | 1 | 2008 | 183 | 0.020 |
Why?
|
| Body Temperature | 1 | 2007 | 116 | 0.020 |
Why?
|
| Receptors, AMPA | 1 | 2007 | 99 | 0.020 |
Why?
|
| Haplorhini | 1 | 1966 | 44 | 0.020 |
Why?
|
| Kinetics | 1 | 2008 | 1047 | 0.020 |
Why?
|
| Base Sequence | 1 | 2008 | 1015 | 0.020 |
Why?
|
| Tablets | 1 | 2006 | 19 | 0.020 |
Why?
|
| Forehead | 1 | 1986 | 13 | 0.020 |
Why?
|
| Serotonin Antagonists | 1 | 2006 | 31 | 0.020 |
Why?
|
| Fear | 1 | 1987 | 239 | 0.020 |
Why?
|
| Vision, Ocular | 1 | 1966 | 68 | 0.020 |
Why?
|
| Brain Mapping | 1 | 1989 | 532 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 1986 | 87 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2006 | 282 | 0.020 |
Why?
|
| Receptors, Opioid, mu | 1 | 2006 | 70 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 1986 | 137 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2007 | 447 | 0.020 |
Why?
|
| Nucleus Accumbens | 1 | 2008 | 417 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2008 | 627 | 0.020 |
Why?
|
| Half-Life | 1 | 2005 | 96 | 0.020 |
Why?
|
| Transaminases | 1 | 1985 | 21 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2007 | 295 | 0.020 |
Why?
|
| Rats | 2 | 2008 | 5300 | 0.010 |
Why?
|
| Retina | 1 | 1966 | 252 | 0.010 |
Why?
|
| Anesthetics, Local | 1 | 2005 | 83 | 0.010 |
Why?
|
| Mice | 2 | 2007 | 8474 | 0.010 |
Why?
|
| Cell Line | 1 | 2008 | 1752 | 0.010 |
Why?
|
| Photoreceptor Cells, Invertebrate | 1 | 2003 | 2 | 0.010 |
Why?
|
| Dementia | 1 | 1986 | 158 | 0.010 |
Why?
|
| Genes, Insect | 1 | 2003 | 4 | 0.010 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2003 | 28 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 1987 | 447 | 0.010 |
Why?
|
| RNA Splicing | 1 | 2003 | 32 | 0.010 |
Why?
|
| Mathematics | 1 | 2003 | 83 | 0.010 |
Why?
|
| Florida | 1 | 2004 | 221 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 2004 | 120 | 0.010 |
Why?
|
| Genotype | 1 | 2006 | 786 | 0.010 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2006 | 266 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 251 | 0.010 |
Why?
|
| Drug Stability | 1 | 2003 | 71 | 0.010 |
Why?
|
| DNA | 1 | 2006 | 597 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 357 | 0.010 |
Why?
|
| Quality Control | 1 | 2003 | 81 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2003 | 156 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2003 | 312 | 0.010 |
Why?
|
| Mass Screening | 1 | 2008 | 843 | 0.010 |
Why?
|
| Computational Biology | 1 | 2003 | 190 | 0.010 |
Why?
|
| ErbB Receptors | 1 | 2003 | 239 | 0.010 |
Why?
|
| Growth Disorders | 1 | 1981 | 21 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 562 | 0.010 |
Why?
|
| Prescription Fees | 1 | 2001 | 5 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1989 | 1615 | 0.010 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2001 | 34 | 0.010 |
Why?
|
| Algorithms | 1 | 2007 | 1196 | 0.010 |
Why?
|
| Protein Binding | 1 | 2003 | 1027 | 0.010 |
Why?
|
| Developmental Disabilities | 1 | 1981 | 119 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2002 | 714 | 0.010 |
Why?
|
| Economics, Nursing | 1 | 1980 | 2 | 0.010 |
Why?
|
| Convalescence | 1 | 1980 | 11 | 0.010 |
Why?
|
| Taste Threshold | 1 | 1980 | 2 | 0.010 |
Why?
|
| Hydrochloric Acid | 1 | 1980 | 19 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1980 | 134 | 0.010 |
Why?
|
| Urea | 1 | 1980 | 51 | 0.010 |
Why?
|
| Sucrose | 1 | 1980 | 58 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 1980 | 136 | 0.010 |
Why?
|
| Calcium | 1 | 2003 | 929 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2007 | 2550 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 1664 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2003 | 1034 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1999 | 137 | 0.010 |
Why?
|
| Limbic System | 1 | 1999 | 106 | 0.010 |
Why?
|
| Temporal Lobe | 1 | 1999 | 125 | 0.010 |
Why?
|
| Internet | 1 | 2001 | 390 | 0.010 |
Why?
|
| Physicians, Family | 1 | 1977 | 83 | 0.010 |
Why?
|
| Patients | 1 | 1977 | 69 | 0.010 |
Why?
|
| Antimanic Agents | 1 | 1997 | 21 | 0.010 |
Why?
|
| Lysergic Acid Diethylamide | 1 | 1976 | 5 | 0.010 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 1997 | 40 | 0.010 |
Why?
|
| Child, Preschool | 2 | 1981 | 3187 | 0.010 |
Why?
|
| Cardiovascular System | 1 | 1997 | 85 | 0.010 |
Why?
|
| Self-Help Groups | 1 | 1976 | 38 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 1980 | 468 | 0.010 |
Why?
|
| Circadian Rhythm | 1 | 1996 | 218 | 0.010 |
Why?
|
| Alprazolam | 1 | 1994 | 35 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2003 | 2689 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 1977 | 442 | 0.010 |
Why?
|
| Aging | 1 | 1980 | 911 | 0.010 |
Why?
|
| Neoplasms | 1 | 1983 | 1667 | 0.010 |
Why?
|
| Paranoid Disorders | 1 | 1991 | 9 | 0.010 |
Why?
|
| Delusions | 1 | 1991 | 20 | 0.010 |
Why?
|
| Stereotyped Behavior | 1 | 1991 | 42 | 0.010 |
Why?
|
| Discrimination Learning | 1 | 1972 | 45 | 0.010 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1991 | 30 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1972 | 532 | 0.010 |
Why?
|
| Memory, Short-Term | 1 | 1972 | 79 | 0.010 |
Why?
|
| Eye | 1 | 1972 | 89 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 1991 | 187 | 0.010 |
Why?
|
| Psychiatric Department, Hospital | 1 | 1991 | 17 | 0.010 |
Why?
|
| Conditioning, Operant | 1 | 1972 | 241 | 0.010 |
Why?
|
| Coffee | 1 | 1988 | 18 | 0.010 |
Why?
|
| Fibrinolytic Agents | 1 | 1972 | 377 | 0.000 |
Why?
|
| Bipolar Disorder | 1 | 1991 | 307 | 0.000 |
Why?
|
| Light Coagulation | 1 | 1966 | 4 | 0.000 |
Why?
|
| Incidence | 1 | 1991 | 1603 | 0.000 |
Why?
|
| Lasers | 1 | 1966 | 61 | 0.000 |
Why?
|
| Liver Function Tests | 1 | 1986 | 114 | 0.000 |
Why?
|
| Cerebral Cortex | 1 | 1988 | 415 | 0.000 |
Why?
|
| Reaction Time | 1 | 1983 | 170 | 0.000 |
Why?
|
| Methods | 1 | 1981 | 156 | 0.000 |
Why?
|
| Touch | 1 | 1981 | 25 | 0.000 |
Why?
|
| Body Height | 1 | 1981 | 67 | 0.000 |
Why?
|
| Adipose Tissue | 1 | 1981 | 221 | 0.000 |
Why?
|
| Joint Diseases | 1 | 1977 | 37 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1977 | 219 | 0.000 |
Why?
|
| Personality | 1 | 1977 | 66 | 0.000 |
Why?
|
| Social Behavior | 1 | 1977 | 164 | 0.000 |
Why?
|
| Diabetes Complications | 1 | 1977 | 249 | 0.000 |
Why?
|
| Infant | 1 | 1981 | 2891 | 0.000 |
Why?
|
| Attitude to Health | 1 | 1977 | 403 | 0.000 |
Why?
|